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Abstract Hereditary cancer predisposition gene testing
allows the identification of individuals at high risk of
cancer that may benefit from increased surveillance,
chemoprevention, and prophylactic surgery. In order to
implement clinical genetic strategies adapted to each
population’s needs and intrinsic genetic characteristic, this
review aims to present the current status of knowledge
about the spectrum of BRCA pathogenic variants in Latin
American populations. We have conducted a comprehen-
sive review of 33 studies published between 1994 and 2015
reporting the prevalence and/or spectrum of BRCA1
(OMIM 113705) and BRCA2 (OMIM 600185) variants.
The combined sample size for these studies consisted of
4835 individuals from 13 countries in Latin America and
the Caribbean, as well as in Hispanics in the United States.
A total of 167 unique pathogenic variants have been
reported in the existing literature. In unselected breast
cancer cases, the prevalence ranged from 1.2 to 27.1 %.
Some countries presented a few recurrent pathogenic
variants, while others were characterized by diverse, non-
recurrent variants. The proportion of BRCA pathogenic
variants shared between Hispanics in the United States and
Latin American populations was estimated at 10.4 %.
Within Latin America and the Caribbean, 8.2 % of the
BRCA variants reported were present in more than one
country. Countries with high prevalence of BRCA patho-
genic variants may benefit from more aggressive testing
strategies, while testing of recurrent variant panels might
present a cost-effective solution for improving genetic
testing in some, but not all, countries.
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Introduction
Worldwide, breast cancer is the most common female
cancer and the most common cause of female cancer-re-
lated death [1]. Breast cancer is a heterogeneous disease
defined by various molecular subtypes, each one with an
associated risk profile and treatment recommendations [2,
3]. Several loci of high, moderate, and low penetrance have
been implicated in inherited risk of breast cancer [4, 5].
The genetic predisposition to breast cancer can be descri-
bed as a continuum from a strong genetic contribution to a
weaker polygenic genetic contribution with an environ-
mental component.
Over 20 years ago, the BRCA1 and BRCA2 genes were
identified as highly penetrant susceptibility genes for
hereditary breast and ovarian cancers [6, 7]. Inactivating
variants in those tumor suppressors account for approxi-
mately 16 % of the familial risk of breast cancer [8] and
represent 5–10 % of all breast cancers [9]. Women carry-
ing a BRCA mutation are estimated to have a cumulative
cancer risk by age of 70 years of up to 87 and 54 % for
breast and ovarian cancer, respectively [10–16]. They also
have modest to marked increases in the lifetime risk of
developing other cancer types such as colorectal, gastric,
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gallbladder and bile duct, malignant melanoma, pancreatic,
prostate, and uterine cancers [10, 14, 16, 17]. The early
identification of individuals at risk by genetic testing has
been shown to be associated with increased surveillance
and risk-reduction strategies ultimately leading to diagno-
sis of early stage tumors and improved outcomes [18, 19].
However, effective identification of BRCA1/2 mutation
carriers depends on the availability and access to genetic
counseling and testing of at-risk individuals.
A significant portion of populations inhabiting Central
and South America as well as certain islands of the Car-
ibbean share an official language derived from Latin,
majorly Spanish or Portuguese. Despite this common her-
itage from the colonization era, each region of Latin
America and the Caribbean (hereby referred to as Latin
America) is often characterized by unique geography,
culture, politics, and socioeconomic factors [20]. In the
USA, Hispanics (defined by the U.S. Census Bureau a
person of Cuban, Mexican, Puerto Rican, South or Central
American—except for Brazil, or other Spanish culture or
origin regardless of race) make up 16.3 % of the population
and accounted for 56 % of the national population growth
between 2000 and 2010, which makes this group the fastest
growing minority in the country [21].
Despite lower incidence of breast cancer in Latin
America populations when compared to Europe or the
USA, the mortality-to-incidence ratio is significantly
higher in the former region [21, 22]. This is in part due to
poor access to cancer care and presentation at later stages
[22]. For instance, it is estimated that 58 % of the breast
cancers in Mexico are detected at stage III–IV [23]. In this
population, the high cost associated with cancer care was
attributed to late diagnosis, suggesting a need for the
implementation of better prevention and detection strate-
gies [24]. However, in several regions of Latin America,
genetic testing is either not available or the associated cost
is still prohibitive for a large proportion of individuals at
risk [22].
There is limited information available regarding popu-
lation-specific risks and very few systematic studies of the
prevalence of genetic variants predisposing to breast cancer
relevant to the populations of Latin America. Here we
review the current knowledge about BRCA1 and BRCA2
variants in women from Latin America, the Caribbean, and
Hispanics in the United States with the objective of iden-
tifying areas in need of further research and avenues for
improving access to genetic testing for hereditary cancers.
The BRCA1 and BRCA2 mutation spectrum in Latin
America
In recent years, increasing accessibility of next-generation
sequencing (NGS) has resulted in its increased use in
clinical genetic testing [25]. NGS approaches allows the
cost-effective interrogation of multiple targets and has
driven the expansion from BRCA1 and BRCA2 testing to
the so-called ‘panel testing,’ in which a number of addi-
tional high- and moderate-penetrance hereditary cancer
genes (demonstrated and suspected) are included [26].
Despite these advances, the cost of comprehensive BRCA1
and BRCA2 analysis is still prohibitive for low income
individuals in these countries. Importantly, although the
technical sensitivity of these assays is very high and vir-
tually all variants can be accurately detected, our ability to
clinically annotate these variants has lagged.
As a solution, amplicon-based single-site panels of
recurrent Latin American BRCA pathogenic variants that
would constitute the first line of screening of at-risk indi-
viduals prior to performing comprehensive BRCA analysis
have been developed. Such model of tiered testing has been
widely successful in the Ashkenazi Jewish population in
which three common pathogenic variants explain 78.4 %
of the cases [27]. The development of a clinically useful
panel in Latin America will require knowledge of the
pathogenic variant spectrum in each region or country and
depend on the presence of recurrent variants explaining a
majority of the hereditary breast and ovarian cancer cases.
To provide a comprehensive picture we have conducted
a literature review of the BRCA1 and BRCA2 variants
identified in Latin America (Supplementary Fig. 1).
Between 1994 and August 2015, 33 publications reported
BRCA variants in populations from 13 countries of Central
and South America, the Caribbean, and Hispanic/Latino
populations from the US. Taken together, these studies
have screened a total of 4835 individuals and identified 167
different pathogenic variants (Supplementary Table 1).
Table 1 summarizes the characteristics of the cohorts, the
prevalence of the BRCA variants reported, and screening
methods for each of the study reviewed.
The size of the cohorts ranged from 19 to 815 individ-
uals, the majority identified through hospital or clinic-
based recruitment strategies (Table 1). Several method-
ological factors preclude a systematic comparison across
studies. There was significant variation in the inclusion
criteria from unselected cases to cases selected for family
history and/or personal history criteria such as age of onset
and tumor molecular profile. Indirect mutation detection
methods or approaches that restrict the search to panels of
known mutations are expected to detect only a fraction of
the variants present in the sample screened. For instance,
the sensitivity of single-stranded conformation polymor-
phism (SSCP) ranges from 50 to 96 %, while conforma-
tion-sensitive gel electrophoresis (CSGE) and for the
protein truncation test (PTT) are estimated to detect only
75 and 76 % of the BRCA1 and BRCA2 variants, respec-
tively [28].


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Breast Cancer Res Treat (2015) 154:441–453 445
123
Early BRCA testing focused on the detection of single
nucleotide variants (point mutations) and small insertions
or deletions rather than large genomic rearrangements. The
prevalence of such rearrangement variants has been shown
to vary significantly in different populations [29]. Large
genomic rearrangements may account for up to 21.4 % of
the BRCA inactivating variants in high-risk patients from
Latin America and the Caribbean [30]. In Hispanics from
the Northern California Breast Cancer Family Registry, the
BRCA1 deletion of exon 9–12 represented over 10 % of the
BRCA1 pathogenic variants identified [31]. In Puerto Rico,
the BRCA2 exon 1–2 deletion is one of the three most
frequent pathogenic variants, accounting for 18 % of the
BRCA cases [32]. Less than half of the studies reviewed
reported screening for large scale rearrangements and only
four reported performing comprehensive screening through
Multiplex Ligation-dependent Probe Amplification
(MLPA) (Table 1). As a result of these factors, the
prevalence and the diversity of the BRCA pathogenic
variants may be underestimated in several of the published
studies.
Despite those limitations, some observations stand out.
In unselected breast cancer cases from Brazil [33],
Colombia [34, 35], Cuba [36], Mexico [37, 38], and Peru
[39], the prevalence ranged between 1.2 and 4.9 %, which
is similar to what has been reported for US non-Hispanic
White populations [40]. One exception is in the Bahamas,
where it is estimated that 27.1 % of breast cancer cases
were carriers of a BRCA pathogenic variant, regardless of
age of onset or family history of cancers [41, 42].
Currently, recommendations to offer genetic testing for
hereditary cancers are based on family history and/or per-
sonal history suggestive of Hereditary Breast and Ovarian
Cancer. Recently, this practice has been challenged and
screening every woman as part of the routine medical
examination has been proposed [43]. The high prevalence
in the Bahamas provides an argument in favor of a more
aggressive BRCA screening approach in such populations.
It is expected that countries for which smaller cohorts
were screened show less diversity in the BRCA variants
identified, not because they are less genetically diverse but
rather as a consequence of the limitations associated with
sample size in characterizing rare variants. This is exem-
plified by Brazil [33, 44–48], Mexico [37, 38, 49–52], and
in US Hispanics [31, 53–57] where the number of different
pathogenic variants detected ranged from 37 to 45 as a
result of over 1300 individuals screened (Table 2). Vari-
ants such as 185delAG, 5382insC, and R1443X are among
the 20 most frequent BRCA1 variants reported by the
Breast Cancer Information Core (BIC) database (http://
research.nhgri.nih.gov/bic/), and it is therefore not sur-
prising that they are recurrent in several countries of Latin
America as well. In contrast, BRCA1 A1708E was among
the 10 most frequent pathogenic variants in Latin America,
observed in four different countries, but is not one of the
most frequent BRCA1 variants overall. This represents an
example of a recurrent pathogenic variant specific to these
populations. Interestingly, the ratio of BRCA1 to BRCA2
carriers also shows significant variations across Latin
America. In most populations, BRCA1 variants are more
frequent than BRCA2, and this holds true for most countries
of Latin America. However, in Costa Rica [58], Cuba [36],
Puerto Rico [32], and Uruguay [59], over 80 % of the
carriers had a pathogenic variant in BRCA2. This obser-
vation has important clinical implications as the charac-
teristics of the cancer spectrum, and tumor pathology is
expected to differ according to the gene mutated [60]. For
instance, BRCA1 and BRCA2 carriers show differences in
both overall risk of developing breast and ovarian cancer
and age distribution of risk [13]. Cancers associated with
BRCA1 germline mutations are more frequently medullary
of high mitotic counts, while BRCA2-associated cancers
have higher score for tubule formation with lower mitotic
counts [61]. Compared to sporadic breast tumors, basal
subtype markers are more common in tumors arising in
BRCA1 carriers [62] but not in BRCA2 carriers [63]. In
contrast, BRCA2-associated tumors are more likely to be of
the luminal subtype and estrogen receptor positive when
compared to controls [64].
In some countries, a few recurrent variants explain the
majority of cases linked to BRCA-inactivation. As a result,
a PCR-based MassARRAY (Sequenom) panel of recurrent
mutations, the HISPANEL, was developed in the US and
validated among US Hispanic and Mexican populations.
Compared with direct sequencing, this approach was esti-
mated to have a sensitivity of 68 % but for a fraction of the
cost, which is an important factor to consider in countries
where resources are limited. Such an approach could be
considered for Colombia where despite having identified
63 carriers in 1195 individuals screened, three recurrent
variants explained over 88 % of the cases [34, 35, 65, 66].
On the other hand, this strategy may not be adequate for
countries such Argentina [67], Uruguay [59], and Vene-
zuela [68] where most recurrent pathogenic variants are not
frequent. (Table 2).
In addition, the question remains whether this panel
could be transferable from one country to another. The
E1308X variant is the most frequent in Puerto Rico and has
been observed in the US but has not been observed in any
other countries of Latin America. Within Latin America,
only 8.02 % (n = 13) of the pathogenic variants reported
were present in two or more countries. Caution should also
be taken in studying US Hispanic to make inferences about
the populations of origin of these immigrants. The BRCA2
6174delT variant was one of the most frequently observed
in Latin America (except for Mexico) but has still not been
446 Breast Cancer Res Treat (2015) 154:441–453
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reported in US Hispanics. Many of the recurrent variants
found in Chile [69, 70] have not been observed in US
Hispanics. Overall, of the 167 BRCA pathogenic variants
identified in this literature review, only 10.4 % (n = 17)
were shared between US Hispanics and Latin America.
While these observations may be the result of the limited
sample sizes available for some of the countries, it suggests
that the Latin America immigrants established in the US
might not represent the genetics of their populations of
origin in their complexity. It is also a reflection of the
demographics of the US Hispanic populations, where
countries like Mexico and Puerto Rico are overrepresented.
As illustrated by the network of interaction of recurrent
BRCA variants between the Latin America countries
(Fig. 1), it can be observed that the most frequent variants
are more likely to be shared across countries, but a sig-
nificant number of recurrent variants are found in one
country only. Therefore, the available data, even though
limited, suggest that the development of a low-cost Latin
American screening panel that would be widely offered is
unlikely as a result of the limited overlap in the spectrum of
reported BRCA1 and BRCA2 variants in Latin America and
US Hispanics.
Population history shaped the BRCA variant
spectrum in Latin America
The genetic makeup of modern populations in Latin
America is a combination of pre-Colombian and colonial
heritage, both in the diversity of the gene pools imported in
the Americas and their subsequent admixture. Accordingly,
heterogeneity in admixture patterns has been shown to vary
significantly across and within the continent [71–76]. From
the 15th century, the European colonial migration to the
New World nearly decimated the Native American popu-
lations [77]. European founders were mainly of Spanish
and Portuguese origin but also reflected the diversity of the
Iberian peninsula [71]. During the Atlantic trade between
1451 and 1870, an estimated nine million slaves were
brought to the Americas from the West Coast of Africa
[78]. In the context of testing for hereditary cancer pre-
disposition variants, data from the 1000 Genomes Con-
sortium demonstrated that rare variants are more likely to
be specific to a continent or country than common variants
[79], suggesting that one should account for the diversity of
the populations inhabiting Latin America when designing
screening and prevention strategies.
Some recurrent pathogenic variants in the populations
from Latin America can be associated with documented
migration events. The origin of the Jewish pathogenic
variant BRCA1 185delAG can be traced back to 1492
when, coinciding with the start of the colonization of the
Americas, Jews were forced to convert or be expelled from
the Iberian Peninsula. In the view of the long-lasting
genetic admixture of Sephardic and Ashkenazi Jews, and
following migration of Jews into the countries of South and
North America, it is not surprising that typical founder
Jewish mutations are commonly found in the modern
Argentina, Peru, Brazil, Chile, and US Hispanics. In some
cases, haplotype analysis has confirmed that the origin of
the 185delAG in populations from Latin America was in
fact the same as the Jewish founder mutation [57].
Fewer recurrent variants are traced back to the African
continent, despite a significant contribution of African
ancestry to the genetic pool of some of the populations of
Latin America. Among the factors proposed to explain, this
Table 2 Recurrent BRCA1 and BRCA2 mutations in Latin America, the Caribbean, and US Hispanics
Country Individuals screened n Carriers n Mutations n Recurrent mutations1 n Carriers with a recurrent
mutation n (%)
Argentina 94 19 19 0 0
Argentina (Ashkenazi Jews) 40 17 3 3 17 (100)
Bahamas 204 47 11 6 42 (89.4)
Brazil 1408 82 37 9 54 (65.9)
Chile 380 40 18 12 30 (75.0)
Colombia 1195 63 10 3 56 (88.9)
Costa Rica 111 5 4 1 2 (40.0)
Cuba 307 7 6 1 2 (28.6)
Mexico 1305 128 45 15 101 (78.9)
Peru 266 13 5 3 11 (84.6)
Puerto Rico 23 11 6 3 8 (72.7)
Uruguay 42 6 6 0 0
US Hispanics 1486 173 41 17 149 (86.1)
Venezuela 58 9 8 1 2 (22.2)
1 For any given country, a recurrent mutation is defined as a mutation identified in more than one unrelated BRCA carriers
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Fig. 1 The network of
recurrent BRCA1 (a) and
BRCA2 (b) pathogenic variants
reported in Latin America, the
Caribbean, and US Latinos.
Recurrent variants have been
reported more than once within
a country and/or have been
observed in more than one
country. The connections
between the nodes generate a
complete system of interactions
between variants and the
countries in which they have
been detected. The nodes
representing the countries are
mapped on the network based
on the proportion of shared
variants with other Latin
America countries. The size of
the nodes representing the
variants is proportional to the
total number of observations,
dashed edges were used for
recurrent variants that were
unique to a country, and thicker
edges indicate variants that are
shared in more countries. The
blue node colors indicate
countries for which at least one
study conducted comprehensive
BRCA1/2 analysis by direct
sequencing, and the green nodes
indicate countries for which
BRCA analysis was conducted
using mutation panels or
indirect analysis methods.
Darker nodes (dark blue or dark
green) indicate countries for
which at least one study
conducted comprehensive large
rearrangement screening, while
the pale node colors (pale blue
or pale green) indicate countries
for which no comprehensive
rearrangements were assessed.
The network was generated with
Cytoscape 3.2.1 [96]
448 Breast Cancer Res Treat (2015) 154:441–453
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observation is the exceptional genetic diversity both within
Africa and in the numerous ethnic groups that were brought
to the Americas during the Atlantic slave trade. One
exception is the BRCA1 943ins10 mutation, which is the
most frequently pathogenic variant reported in African-
Americans by Myriad Genetics Laboratories, representing
10 % of the 279 African-American BRCA pathogenic
variants [80]. The presence of a single haplotype in fami-
lies from the Ivory Coast, Florida, Southeastern US, and
the Bahamas is consistent with a founder effect originating
in West Africa [81].
Taken together, these examples indicate that the muta-
tion spectrum of each Latin American population is
expected to be strongly linked to their migration history.
Hence, one could extrapolate that the extent of the overlap
in the frequent BRCA mutations observed between coun-
tries will be, at least in part, determined by the shared
events and interchanges that characterize the migration
history of each geographical region. The BRCA1 deletion
of exons 9–12 is a recurrent pathogenic variant observed in
unrelated families of Mexican origin, which are geo-
graphically dispersed in the US [31, 82]. Haplotype anal-
ysis pointed to a founder effect of a variant that would have
originated in Amerindian or Mestizo populations [82].
Other examples include a BRCA1 3450del4 identified in
multiple breast and ovarian cancer patients from Brazil [45,
47], Chile [70], and Colombia [34, 35, 65, 66], which is
also common in breast cancer populations from Spain [83]
and Portugal [84]. In contrast, the BRCA1 5382insC
founder pathogenic variant is most frequently reported in
Brazil by several independent studies [33, 44, 45, 48] but
has not been observed elsewhere in South America with the
exception of an Ashkenazi community in Argentina [67].
This indicates that the genetic background of the Latin
American populations is also shaped by events leading to
unique population structures within and between countries.
Caution should be taken when making inferences about
the origin of BRCA variants based solely on the co-oc-
currence in two populations. In the absence of haplotype
analysis, one cannot distinguish whether a variant has
migrated from one historically linked geographic area to
another or is the result of independent mutational events.
Therefore, not all carriers of the recurrent pathogenic
variants or well-known founder mutations are expected to
share a common ancestor. For example, BRCA2 3034del4
is a recurrent variant, which was also observed as a de novo
germline mutation in a case of early onset breast cancer
with no strong family history of cancer [85]. In families of
Northern Europe Caucasian ancestry, this same mutation
was observed in seven different countries and showed
considerable haplotype diversity [86]. Haplotype analyses
have identified multiple origins for several other recurrent
mutations, including BRCA1 185delAG [87]. This suggests
that some regions of the BRCA1 and BRCA2 genes might
be prone to mutations. It is also noteworthy in light of the
small proportion of studies who conduct mutation screen-
ing in the context of haplotype analysis. Finally, de novo
variants may also be underreported as the majority of
individuals undergoing BRCA testing are selected for
having strong family history of cancer.
Cancer genetic testing awareness and access in Latin
American populations
While hereditary clinical testing of Latin American and US
Hispanic populations could greatly benefit from a better
understanding of the mutation spectrum in the BRCA
genes, social-economic aspects of genetic testing will also
need to be addressed to improve access. In its policy
statement on genetic and genomic testing, ASCO empha-
sizes the role of the informed consent process and recom-
mends that cancer genetic susceptibility testing be
conducted in the context of pre- and post-testing genetic
counseling [88]. Positive outcomes associated with testing
may be limited in the absence of genetic counseling and
integrated clinical management structure ensuring that
carriers are engaged in appropriate screening and preven-
tion programs. Given that Hispanics in the US are 1.8 times
more likely to receive an inconclusive result (variant of
uncertain significance) [80], the participation of genetics
professionals pre- and post-testing becomes especially
important to provide support to the patients and physicians.
Finally, a negative test results in the absence of a known
mutation in the family may provide a false reassurance,
especially when testing is not conducted in the context of
extended panels of genes [89].
Studies reporting on awareness and access to genetic
testing in Latin America are sparse, but the situation in the
US has been more documented. In a cross-sectional anal-
ysis of 46,276 women who underwent BRCA genetic test-
ing between 1996 and 2006, only 4.2 % were of Latin
American ethnicity [80]. In a US sample of 1414 women
diagnosed with breast cancer at or before 40 years of age
between 2004 and 2007, Hispanic women were signifi-
cantly less likely to be tested for BRCA1 and BRCA2
mutations [90]. This disparity in access to cancer genetic
testing is especially alarming knowing that the Hispanic
population accounts for approximately 16.3 % of the US
population [21]. Genetic testing awareness has been shown
to be significantly lower in Hispanics of the US when
compared to non-Hispanic whites [91]. Acculturation,
especially the use of the English language, strongly cor-
related with awareness of genetic testing for cancer in the
US [92]. Once informed, participants held favorable atti-
tudes toward risk assessment and counseling [93, 94]. In
some parts of Latin America, limited resources both
Breast Cancer Res Treat (2015) 154:441–453 449
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monetary and in the availability of trained genetic profes-
sional may impede accessibility to cancer genetic testing.
Recently, BRCA1/2 telephone counseling was shown to be
as effective in providing psychological support and guiding
informed decisions [95]. This might contribute to improve
access to genetic counseling in Latin American, especially
in rural setting.
Conclusions
Therefore, for the populations of Latin America and US
Hispanics to benefit from genetic-based cancer prevention
options, a strategy that combines acquiring a better
knowledge of the variants underlying hereditary cancers in
those population and improved access to genetic testing
will need to be developed. From the data available, the
following recommendations emerge: (1) If panels of
mutation are the only economically feasible approach, they
should be developed after comprehensive analysis of a
large series of samples rather than testing panels that have
been developed from other populations; (2) large genomic
rearrangements should be included; and (3) proper clinical
infrastructure including genetic counseling should be
widely available.
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